Management came through in 2013 and looks poised to continue in 2014, imho. The stock price tripled in 2013 due to very real progress (looks beefy to me - & reflected in SP):
1. Uplisting to NYSE MKT
2. Construction start of new cGMP manufacturing plant for clinical trial materials
3. Successful completion of range-finding Tox study for FluCide (no significant Tox effects)
4. Sufficient additional funding to get through clinical trials for FluCide and DengueCide
5. PHE/LRRI agreements for testing of MERS-CoV, H7N9, etc.
6. Progress on HIV-Cide, EKC-Cide, other drug candidates
It may be important to note that I am a more recent investor in NNVC starting in early 2013. I look at some PRs from earlier years and see that management previously set goals that were overly ambitious in terms of timing - especially for a novel biotech.
But there is no denying the momentum and progress that has ramped up over the last year - or the number of potential catalysts this year for the SP as the company completes steps toward FluCide clinical trials.
No one should be under the impression that there are any guarantees in Biotech investing - in NNVC or any other company. So caution is understandable.
My own investment take on NNVC is that I don't want to be out of the stock over the next year - despite likely ups and downs in the SP. The company may be releasing PRs at any time for each step toward the clinical trials.
From my perspective, I am looking for an IND filing to FDA/EMA/TGA by the end of 2014 with the trial starting in 2014 or Q1 2015, a goal communicated by NNVC management. If they don't meet the goal, I will reassess my investment then. But if they do meet the goal, I think there is a very good chance of a doubling or so in share price in 2014 to go on top of the tripling in share price in 2013.
Market Data 
Markets 
